Century Therapeutics(US:IPSC)2026-03-12 12:05Financial Performance - Century Therapeutics reported collaboration revenue of $109.2 million for the year ended December 31, 2025, a significant increase from $6.6 million in 2024[10] - Research and development expenses decreased to $95.7 million in 2025 from $107.2 million in 2024, primarily due to reduced personnel and manufacturing costs[10] - General and administrative expenses were $24.0 million for 2025, down from $33.2 million in 2024, attributed to lower legal fees and stock-based compensation[10] - The net loss for the year ended December 31, 2025, was $9.6 million, a substantial reduction from a net loss of $126.6 million in 2024[10] - Cash, cash equivalents, and marketable securities totaled $117.1 million as of December 31, 2025, down from $220.1 million a year earlier[10] Product Development - CNTY-813, the lead program for type 1 diabetes, is on track for an IND submission in the fourth quarter of 2026, with initial clinical data expected in the second half of 2027[4] - CNTY-308, a CD19-targeted CAR-iT cell therapy, is projected to enter the clinic in 2026 following IND-enabling studies[7] - The company generated compelling preclinical data for CNTY-813, demonstrating maintenance of normoglycemia in animal models for over 6 months[4] Corporate Governance - Century appointed two new members to its Board of Directors in December 2025, enhancing its governance structure[7] Financing Activities - Century completed an oversubscribed private placement financing of $135 million in January 2026, extending its cash runway into the first quarter of 2029[5]